TARGINACT Prolonged-release tablet Ref.[107033] Active ingredients: Naloxone Oxycodone Oxycodone and Naloxone

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2023  Publisher: Napp Pharmaceuticals Ltd, Cambridge Science Park, Milton Road, Cambridge CB4 0GW

Product name and form

Targinact 10 mg/5 mg prolonged-release tablets.

Pharmaceutical Form

Prolonged-release tablet.

White, oblong tablets, with a nominal length of 9.5 mm and with a film coating, embossed “OXN” on one side and “10” on the other side.

Qualitative and quantitative composition

Each prolonged-release tablet contains 10 mg of oxycodone hydrochloride equivalent to 9 mg oxycodone and 5 mg naloxone hydrochloride as 5.45 mg of naloxone hydrochloride dihydrate equivalent to 4.5 mg naloxone.

Excipient with known effect: Each prolonged-release tablet contains 61.0 mg lactose anhydrous.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Naloxone

Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine.

Oxycodone

Oxycodone is a full opioid agonist with no antagonist properties. It has an affinity for kappa, mu and delta opioid receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. The therapeutic effect is mainly analgesic, anxiolytic, antitussive and sedative.

Oxycodone and Naloxone

Oxycodone and naloxone have an affinity for kappa, mu and delta opiate receptors in the brain, spinal cord and peripheral organs (e.g. intestine). Oxycodone acts as opioid-receptor agonist at these receptors and binds to the endogenous opioid receptors in the CNS. By contrast, naloxone is a pure antagonist acting on all types of opioid receptors. Naloxone counteracts opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

List of Excipients

Tablet core:

Ethylcellulose
Stearyl alcohol
Lactose monohydrate
Talc
Magnesium stearate
Povidone K30

Tablet coat:

Polyvinyl alcohol, partially hydrolysed
Titanium dioxide (E171)
Macrogol 3350
Talc

Pack sizes and marketing

PVC/aluminium foil blisters:

Pack sizes: 10, 14, 20, 28, 30, 50, 56, 60, 98 or 100 tablets.

Hospital pack: 100 (10 × 10) tablets.

HDPE bottles with a child-resistant PP closure:

Pack size: 100 tablets.

Not all pack sizes and container types may be marketed.

Marketing authorization holder

Napp Pharmaceuticals Ltd, Cambridge Science Park, Milton Road, Cambridge CB4 0GW

Marketing authorization dates and numbers

PL16950/0157

31/05/2011

Drugs

Drug Countries
TARGINACT Cyprus, Ecuador, Estonia, Croatia, Netherlands, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.